Key facts
- Notable investors include Guangzhou Jinkong Fund, Leadway Capital, Shenzhen Xipeng Private Equity Investment Fund, Tianhe Investment, Wanlian Securities Investment — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Huateng Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Huateng Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huateng Biology
Developer of innovative drugs, gene and cell therapy designed to promote medical innovation and safeguarding life and health. The company offers gene editing, surgical modeling, chemical diet induction and other advanced technologies to build animal models of human diseases, thereby enabling to provide a powerful tool platform for biomedical research and development.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 12
- Website
- htscience.com/
- Ownership
- Privately Held (backing)
Huateng Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huateng Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huateng Biology in its N-PORT filings yet. We sweep new filings monthly.